How Covid-19 rocked the biosimilar market
In April 2020, just as the pandemic was starting to take full effect, the EMA had approved 58 biosimilars . It was a growing market, and the pandemic - and the inevitable economics constraints - actually brought biosimilars front and centre.
Following the 2008 recession, governments turned to biosimilars as a means of saving. Before long, the narrative around generics offering a lower efficacy rate was forgotten, and biosimilars were hailed as the answer to delivering effective healthcare solutions on a tighter budget. Although the market was in a unique position compared to other industries, it still faced many hurdles throughout the pandemic. Read on to hear how Covid-19 rocked the biosimilar market.
A challenge for companies focused on biosimilars
Over the years, several companies have started to distance their operations from the biosimilar market. Just take Merck, who have separated their biosimilars to be produced under the name of a different company. However, that does not mean to say there is lower competition. In fact, there are new companies on the scene, like Coherus Biosciences, which are snapping up newly available market share and establishing themselves as biosimilar-only businesses.
2020 marked the end of many blockbuster biologics patents in the US, such as Truvada, Chantix, Forteo, Ciprodex, and Afinitor. It was set to be a big year for the market, but for those focused on biosimilars, there were some obstacles to face.
Stagnation in the approval of non-Covid therapeutics
Before the outbreak of coronavirus, GlobalData found that 24% of survey respondents believed that ‘patent expiry of biologics’ was a top trend expected to have a positive impact on the pharmaceutical market . This was the most popular response, above M&A mega-deals and the vertical integration of the healthcare system. However, 2020 was the slowest year for approvals in the US market since 2016, with the FDA approving only three biosimilars . Many industry leaders have pointed out that this delay in the approval process has caused businesses to push back their launch dates, thereby flattening market growth.
Delays for products in the pipeline
When drugs lose patent protection, this creates new opportunities for biosimilar companies. A patent will typically last around 20 years from the moment a company files an application. This period gives exclusive rights to the drug inventor, after which competing companies can launch a biosimilar. Though the market was on track for a good year, the pandemic threatened to derail product pipelines. During the height of the outbreak, resources were diverted away from the research and development of new biosimilars and towards the fight against Covid-19 .
Logistical problems
In our report – The impact of biosimilar competition in Europe – we found that in 2020, biosimilar medicines reached a value of €8.4 billion, representing 9% of the total biologics market. But as the virus spread and operations were turned on their head, it soon became clear there would be a disruption to the supply chain. Raw materials could no longer reach their intended destination, and this brought the production of biosimilars to a grinding halt in some cases. But with a Covid-19 vaccine developed and deployed in record-breaking time, the market can breathe a sigh of relief knowing that these operations are steadily returning to normal.
Find your next job with IQVIA
It’s been a challenging year for biosimilar companies and the wider pharmaceutical industry, but there’s never been a better time to search for your next job. At IQVIA, we help our clients bring their biosimilar to market faster by tapping into unparalleled data, technology, advanced analytics, and scientific expertise. If you want to be a part of our mission, browse our e-detailing representative jobs and find out where you can take your biosimilar career with IQVIA. Or, browse all jobs to see what other job opportunities we can offer you.
im
Find out more about life at IQVIA
Did you know IQVIA has
Excellent work-life balance
and is committed to this kind of culture
Did you know IQVIA has
Countless development opportunities
for personal and professional growth
Did you know IQVIA cares about
Health and Wellbeing
for all its employees
Did you know IQVIA has
1,900+ epidemiologists
and real world insight experts
Did you know IQVIA has
4,600 data scientists
including statisticians and analytics developers
Did you know IQVIA has
86,000+ employees
from clinicians to data scientists each transforming healthcare in 100+ countries
Did you know IQVIA has
56+ petabytes of unique data
including 1.2B+ non-identified patient records
Did you know IQVIA has
56+ petabytes of unique data
including 1.2B+ non-identified patient records
Did you know IQVIA has
Excellent work-life balance
and is committed to this kind of culture
Did you know IQVIA has
4,600 data scientists
including statisticians and analytics developers
Did you know IQVIA has
86,000+ employees
from clinicians to data scientists each transforming healthcare in 100+ countries
Did you know IQVIA has
Countless development opportunities
for personal and professional growth
Did you know IQVIA has
1,900+ epidemiologists
and real world insight experts
Did you know IQVIA cares about
Health and Wellbeing
for all its employees
Related jobs
We are sorry but your search has returned no results.
Please try some of the links below to find what you are looking for:
Just following on from the amazing news I got yesterday I wanted to say a really special thank you for all the help and support you have provided throughout the entire recruitment process.
Once again I cannot thank you enough for not only approaching me with this opportunity but also for all the support you’ve given me along the way!
Since joining IQVIA I have had unrivalled support and development from my manager to enable me to aspire to move into secondary care. I feel like my career is strongly supported by my manager in order to maximise my potential.
IQVIA has been behind my development to become a MSL. The contracts that I have worked on have allowed me to push clinical projects with a recent opportunity to manage a pilot scheme integrating e-detailing into an established field based team. The result was an increase in sales.
A quick note to say thank you for your time this morning discussing my future career options. As you know I was feeling very conflicted about the right decision. Discussing the role with you gave me chance to clarify what is important to me.
A quick note to say thank you for your time this morning discussing my future career options. As you know I was feeling very conflicted about the right decision. Discussing the role with you gave me chance to clarify what is important to me.
IQVIA Related insights
Teaser
Medical Sales & ServicesContent Type
ArticlePublished
24/10/2024
Summary
We caught up with Diana Heres, a Service Development Executive at IQVIA Interface, on her career development journey with us so far. Diana shares her journey to help answer questions such as “How do
by
Ruth Lynn
Teaser
GeneralContent Type
ArticlePublished
08/10/2024
Summary
Recently, we interviewed Corinne Scott, Client Services Manager at IQVIA for her insight into how to decide a career change. Corinne shared her own journey and valuable advice with us to help answer
by
Corinne Scott
Teaser
SalesContent Type
ArticlePublished
04/10/2024
Summary
Virtual Sales has a growing presence in the healthcare and medical solutions industry, especially since the pandemic. Virtual Sales is set to be the new normal, even as we’ve emerged on the other side
Teaser
GeneralContent Type
ArticlePublished
27/09/2024
Summary
Kickstarting or switching your career is only made easier by having solid technical skills under your belt. Technical skills are expertise and specialised knowledge that you enhance throughout your c
by
Ruth Lynn
Teaser
SalesContent Type
ArticlePublished
18/09/2024
Summary
If you’re a recent or soon-to-be graduate of biomedical science, and have realised that a laboratory-based career may not be the right direction for you, you may be wondering what other career opti
by
Tracey Smith
Teaser
Medical Sales & ServicesContent Type
ArticlePublished
17/09/2024
Summary
Stepping into any role in the healthcare sector comes with its challenges, and being a successful medical sales representative is no exception. Whether you’re an experienced sales rep and feel confi
by
Ruth Lynn
Teaser
Medical Affairs & ServicesContent Type
ArticlePublished
13/08/2024
Summary
Medical Affairs is a fast-paced sector and the work is so varied that no two days will look the same. Medical affairs professionals working in the pharmaceutical, biotechnology and medical device in
Teaser
Medical Affairs & ServicesContent Type
ArticlePublished
31/07/2024
Summary
At IQVIA, we recruit for various roles within the MedTech sphere and we’re always looking for professionals keen to move healthcare forward. In this article, we’ll outline the market for MedTech so
by
Tracey Smith
Teaser
MedicalContent Type
ArticlePublished
30/07/2024
Summary
In IQVIA, we support customers in their mission to get drugs to patients. As such, we recognise the value of keeping track of the latest market trends, developments, and insights. Modern healthcare
by
Catherine Scott
Teaser
Clinical OperationsContent Type
ArticlePublished
23/07/2024
Summary
Clinical pharmacology, a specialised branch of biomedical science, holds a pivotal role in developing vital drugs and ensuring their effective use in patients. Clinical pharmacologists bridge the ga
by
Ruth Lynn
Teaser
SalesContent Type
ArticlePublished
23/07/2024
Summary
Oncologists focus on diagnosing and treating cancer while overseeing treatment and managing post-treatment care. The oncology drugs market worldwide is expected to reach a market volume of $268bn by
by
Ruth Lynn
Teaser
GeneralContent Type
ArticlePublished
17/07/2024
Summary
Market access is all about preparing a drug for market entry, and as such it’s a vitally important part of the drug development process and wider pharmaceutical industry. While for pharmaceutical an
Recently viewed jobs